货号:A508747
同义名:
(±)-舒必利
/ rac-Sulpiride; Dolmatil
Sulpiride是一种典型的抗精神病药,通过结合多巴胺D2受体发挥作用,常用于研究精神分裂症和抑郁症。
HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | D1 receptor ↓ ↑ | D2 receptor ↓ ↑ | D3 receptor ↓ ↑ | D4 receptor ↓ ↑ | D5 receptor ↓ ↑ | DAT ↓ ↑ | Dopamine receptor ↓ ↑ | 其他靶点 | 纯度 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Penfluridol |
+
Dopamine receptor, Ki: 1.6 μM |
98% | |||||||||||||||||
| Ansofaxine HCl |
++
Dopamine receptor, IC50: 491 nM |
99% | |||||||||||||||||
| Tetrahydroberberine |
+
D2 receptor, pKi: 6.08 |
98+% | |||||||||||||||||
| Prochlorperazine Maleate | ✔ | 98% (HPLC) | |||||||||||||||||
| Olanzapine | ✔ | 99+% | |||||||||||||||||
| Trifluoperazine |
++++
Dopamine D2 receptor, IC50: 1.1 nM |
98% | |||||||||||||||||
| Ropinirole HCl |
++
D2 receptor, Ki: 29 nM |
99% | |||||||||||||||||
| Lurasidone |
++++
D2 receptor, Ki: 1 nM |
98% | |||||||||||||||||
| Levosulpiride | ✔ | 99+% | |||||||||||||||||
| Pridopidine | ✔ | 95% | |||||||||||||||||
| Metoclopramide | ✔ | ✔ | 99+% | ||||||||||||||||
| Molindone HCl | ✔ | 99% | |||||||||||||||||
| Sulpiride | ✔ | 99+% | |||||||||||||||||
| Perospirone |
++++
D2 receptor, Ki: 1.4 nM |
99% | |||||||||||||||||
| Perospirone HCl |
++++
D2 receptor, Ki: 1.4 nM |
99% | |||||||||||||||||
| Phenothiazine | ✔ | 98% | |||||||||||||||||
| Pimozide |
+
Dopamine D1 receptor, Ki: 6600 nM |
+++
Dopamine D2 receptor, Ki: 3.0 nM |
++++
Dopamine D3 receptor, Ki: 0.83 nM |
98% | |||||||||||||||
| Rotundine |
++
D1 receptor, IC50: 166 nM |
+
D2 receptor, IC50: 1.47 μM |
+
D3 receptor, IC50: 3.25 μM |
98% | |||||||||||||||
| Domperidone | ✔ | 99+% | |||||||||||||||||
| ONC206 | ✔ | 99% | |||||||||||||||||
| Pimethixene maleate |
++
Dopamine D1 Receptor, pKi: 6.37 |
+++
Dopamine D2 Receptor, pKi: 8.19 |
++
Dopamine D4.4 Receptor, pKi: 7.54 |
97% | |||||||||||||||
| Loxapine succinate |
++
D1 receptor (human), Ki: 26 nM D2 receptor (Human), Ki: 62 nM |
++
D2 receptor (human), Ki: 24 nM D2 receptor (bovine), Ki: 26 nM |
+++
D4 receptor (human), Ki: 7.5 nM |
98% | |||||||||||||||
| Chlorprothixene |
+++
D1 receptor, Ki: 18 nM |
+++
D2 receptor, Ki: 2.96 nM |
+++
D3 receptor, Ki: 4.56 nM |
+++
D5 receptor, Ki: 9 nM |
99% | ||||||||||||||
| SCH-23390 HCl |
++++
D1 dopamine receptor, Ki: 0.2 nM |
++++
D5 dopamine receptor, Ki: 0.3 nM |
98% | ||||||||||||||||
| MPP+ iodide | ✔ | 97% | |||||||||||||||||
| σ1 Receptor antagonist-1 |
+
DAT, pKi: 5.8 |
97% | |||||||||||||||||
| Benztropine mesylate |
++
DAT, IC50: 118 nM |
98% | |||||||||||||||||
| Azaperone | ✔ | 98% | |||||||||||||||||
| Ziprasidone HCl | ✔ | 98+% | |||||||||||||||||
| Paliperidone | ✔ | 98% | |||||||||||||||||
| Alizapride HCl | ✔ | 99+% | |||||||||||||||||
| Amisulpride | ✔ | 98% | |||||||||||||||||
| Quetiapine hemifumarate | ✔ | Adrenergic Receptor | 98% | ||||||||||||||||
| Clozapine N-oxide | ✔ | 99% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Sulpiride is a substituted benzamide with selective dopaminergic blocking activity. Sulpiride was selective for dopamine (D)2 receptors and also blocks D3 and D4 receptors. Sulpiride does not block D1, adrenergic, cholinergic, gamma-aminobutyric acid-ergic, histaminergic, or serotonergic receptors to an appreciable extent. The oral bioavailability of sulpiride is poor, with estimates approximating 35%. Sulpiride may cause extrapyramidal effects, autonomic effects, tardive dyskinesia, and the neuroleptic malignant syndrome[3]. At low dosages (50 to 150 mg/day), sulpiride produces a disinhibiting and antidepressant effect, which is probably related to its action on D2 presynaptic autoreceptors, thus facilitating dopaminergic neurotransmission[4]. Sulpiride and melatonin reduce tinnitus perception, decreasing dopamine activity[5]. Sulpiride attenuated by 36% the anorexia produced by intrahypothalamic injections of amphetamine[6]. |
| Concentration | Treated Time | Description | References | |
| HCMEC/D3 cells | 1, 5, 25 µM | 2 minutes | To study the transport of Sulpiride in brain microvascular endothelial cells, results showed a carrier-mediated uptake mechanism | AAPS J. 2014 Nov;16(6):1247-58. |
| MDA-MB-231 cells | 50 µM | 48 hours | To evaluate the effect of sulpiride and dexamethasone combination on colony formation, results showed the combination significantly inhibited colony formation | Acta Pharmacol Sin. 2017 Sep;38(9):1282-1296. |
| 4T1 cells | 50 µM | 48 hours | To evaluate the effect of sulpiride and dexamethasone combination on colony formation, results showed the combination significantly inhibited colony formation | Acta Pharmacol Sin. 2017 Sep;38(9):1282-1296. |
| Administration | Dosage | Frequency | Description | References | ||
| Rats | MAM-E17 schizophrenia model rats | Bilateral microinjection into the ventral pallidum | 0.1 μg, 1.0 μg, 4.0 μg | Single administration | To investigate the effects of sulpiride on locomotor activity and conditioned place preference in MAM-E17 rats. The results showed that larger doses of sulpiride reduced locomotor activity and restored habituation disturbance in MAM-E17 animals. Additionally, the largest dose of sulpiride induced CPP in SAL-E17 animals but not in MAM-E17 animals. | Sci Rep. 2024 May 29;14(1):12305 |
| Wistar rats | Ventral pallidum microinjection model | Bilateral ventral pallidum microinjection | 0.1 μg, 1.0 μg, and 4.0 μg per side | Single injection followed by behavioral observation | To investigate the effects of sulpiride on spatial learning and conditioned place preference. Results showed that intra-VP sulpiride dose-dependently impairs learning processes, but the largest dose induces place preference. | Sci Rep. 2022 Nov 10;12(1):19247 |
| Zebrafish | Cocaine-induced conditioned place preference model | Water exposure | 10 μM | 45 minutes exposure followed by behavioral testing | To investigate the effect of sulpiride on cocaine-induced conditioned place preference. Results showed that sulpiride completely blocked cocaine-induced CPP. | Pharmacol Biochem Behav. 2012 Dec;103(2):157-67 |
| Sprague-Dawley rats | Healthy rats | Oral | 15 mg/kg | Single dose | To evaluate the pharmacokinetic parameters of sulpiride lipospheres, showing a 3.4-fold improvement in oral bioavailability | Int J Nanomedicine. 2021 Mar 9;16:2013-2044 |
| Zebrafish (AB strain) | Zebrafish | Water exposure | 20 ng/L, 50 ng/L, 100 ng/L | Half of the water replaced daily for 14 days | To investigate the effects of sulpiride and clozapine on dopaminergic (DAergic) and serotonergic (5-HTergic) neurotransmitter systems in the brain of zebrafish. Results showed that sulpiride and clozapine interfered with DAergic and 5-HTergic neurotransmitter systems in the telencephalon and diencephalon of zebrafish, leading to abnormal mRNA and protein levels of key functional molecules in DA and 5-HT signaling pathways. | Sci Rep. 2022 Oct 26;12(1):17973 |
| Nude mice | Human breast cancer MCF-7/Adr xenograft model | Oral | 25 or 50 mg/kg | Daily administration | SUL significantly enhanced the inhibitory effect of DEX on the growth of drug-resistant breast cancer by antagonizing D2DR, indicating the involvement of a CSC-related mechanism | Acta Pharmacol Sin. 2019 Dec;40(12):1596-1602 |
| C57BL/6J mice | Brain slice model | Recirculating perfusion | 5 μM | Single 50 ms flash | Block D2 receptors and measure dopamine dissociation rates | ACS Chem Neurosci. 2020 Mar 18;11(6):939-951 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.93mL 0.59mL 0.29mL |
14.64mL 2.93mL 1.46mL |
29.29mL 5.86mL 2.93mL |
|
| CAS号 | 15676-16-1 |
| 分子式 | C15H23N3O4S |
| 分子量 | 341.43 |
| SMILES Code | O=C(NCC1N(CC)CCC1)C2=CC(S(=O)(N)=O)=CC=C2OC |
| MDL No. | MFCD00055061 |
| 别名 | (±)-舒必利 ;rac-Sulpiride; Dolmatil; Equilid; Enimon; CCRIS-4248; (S)-Sulpiride; (RS)-(±)-Sulpiride; RD 1403; (±)-Sulpiride; Dogmatil; Aiglonyl; Sulpyrid; Dobren |
| 运输 | 蓝冰 |
| InChI Key | BGRJTUBHPOOWDU-UHFFFAOYSA-N |
| Pubchem ID | 5355 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, room temperature |
| 溶解方案 |
DMSO: 105 mg/mL(307.53 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1